Maiwald
Lawyers at Maiwald and Sterne Kessler analyse how patents with claims directed to medical treatments are handled in the US and in Europe
Sponsored
Sponsored
-
Sponsored by MaiwaldA shift is required in the finance and banking sectors’ approach to the use of intangible capital assets as collateral, says Marco Stief of Maiwald -
Sponsored by MaiwaldMarco Stief of Maiwald explains a ruling by the Düsseldorf Regional Court in the matter NuCana v Gilead that establishes the subsidiarity of the objection of disproportionality with regard to a compulsory licensing action
-
Sponsored by MaiwaldSusanna Heurung of Maiwald examines a decision by the European Court of Justice concerning the ending of a period of ‘acquiescence’ in a trademark case and what it means for potential plaintiffs
-
Sponsored by MaiwaldOwners of German trademarks who rely on their use in Switzerland to protect their mark must change their strategy immediately, as Susanna Heurung of Maiwald explains
-
Sponsored by MaiwaldHeike Röder-Hitschke of Maiwald discusses a significant European Court of Justice (CJEU) ruling, and how it will affect future practice in preliminary injunction proceedings
-
Sponsored by MaiwaldSimon Lud of Maiwald explains how a German court judgment is advantageous for patent applications in the fields of artificial intelligence and quantum computing
